Drug Information Analysis Service

Prendiville JS Hebert AA Greenwald MJ Esterly NB . Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881–7.

Yetiv JZ Bianchine JR Owen JA . Etiologic factors of the Stevens Johnson syndrome. S Med J 1980; 73: 599–602.

Bianchine JR MacAraeg PVJ Lasagna L Azarnoff DL Brunk SF Hvidberg EF Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med 1968; 44: 390–405.

Crosby SS Murray KM Marvin JA Heimbach DM Tartaglione TA . Management of Stevens-Johnson syndrome. Clin Pharm 1986; 5: 682–9.

Gottschalk HR Stone OJ . Stevens-Johnson syndrome from ophthalmic sulfonamide. Arch Dermatol 1976; 112: 513–4.

Marvin JA Heimbach DM Engrav LH Harnar TJ . Improved treatment of the Stevens-Johnson syndrome. Arch Surg 1984; 119: 601–5.

Product information. Silver sulfadiazine cream. Lincolnshire, IL: Boots Pharmaceuticals, September 1991.

Lockhart SP Rushworth A Azmy AAF Raine PAM . Topical silver sulfadiazine: Side effects and urinary excretion. Burns 1983; 10: 9–12.

Kulick MI Wong R Okarma TB Palces E Berkowitz RL . Prospective study of side effects associated with the use of silver sulfadiazine in severely bumed patients. Ann Plast Surg 1985; 14: 407–18.

Mandell GL Sande MA . Antimicrobial agents. In: Gilman AG Rall TW Nies AS Taylor P , eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1047–64.

Bayer AS . Infective endocarditis. Clin Infect Dis 1993; 17: 13–22.

Karchmer AW . Staphylococcal endocarditis. Am J Med 1985; 78 (suppl 6B):116–27.

Threlkeld MG Cobbs CG . Infectious disorders of prosthetic valves and intravascular devices. In: Mandell GL Douglas RG Bennet JE , eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 706–15.

Mansur AJ Grinberg M da Luz Lemos P Belloti G . The complications of infective endocarditis. Arch Intern Med 1992; 152: 2428–32.

Whitener C Caputo GM Weitekamp MR Karchmer AW . Endocarditis due to coagulase-negative staphylococci: Microbiologic, epidemiologic, and clinical considerations. Infect Dis Clin North Am 1993; 7: 81–96.

Arber N Militianu A Ben-Yehuda A Krivoy N Pinkhas J Sidi Y . Native valve Staphylococcus epidermidis endocarditis: Report of seven cases and review of the literature. Am J Med 1991; 90: 758–62.

Bisno AL Dismukes WE Durack DT Kaplan EL Karchmer AW Kaye D Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA 1989; 261: 1471–7.

Archer GL . Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices. Antimicrob Agents Chemother 1978; 14: 353–9.

Bailey EM Constance TD Albrecht LM Rybak MJ . Coagulase-negative staphylococci: Incidence, pathogenicity, and treatment in the 1990s. DICP Ann Pharmacother 1990; 24: 714–20.

Zaske DE . Aminoglycosides. In: Evans WE Schentag JJ Jusko WJ , eds. Applied Pharmacokinetics. Vancouver, WA: Applied Therapeutics, 1992: 14–1–14–47.

Dahlgren JG Anderson ET Hewitt WL . Gentamicin blood levels: A guide to nephrotoxicity. Antimicrob Agent Chemother 1975; 8: 58–62.

Zhanel GG . Once daily aminoglycoside dosing: The result of research on antimicrobial pharmacodynamics. Am J Pharmaceut Educ 1992; 56: 164–7.

Gilbert DN . Once-daily dosing aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399–405.

Lowy FD Chang DS Lash PR . Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother 1983; 23: 932–4.

Kobasa WD Kaye KL Shapiro T Kaye D . Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5 (suppl):S533–7.

Lowy FD Wexler MA Steigbigel NH . Therapy of methicillin-resistant Staphylococcus epidermidis experimental endocarditis. J Lab Clin Med 1982; 100: 94–104.

Chamovitz B Bryant RE Gilbert DN Hartstein AI . Prosthetic valve endocarditis caused by Staphylococcus epidermidis. JAMA 1985; 253: 2867–8.

Caputo GM Archer GL Calderwood SB DiNubile MJ Karchmer AW . Native valve endocarditis due to coagulase-negative staphylococci. Am J Med 1987; 83: 619–25.

Karchmer AW Archer GL Dismukes WE . Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98: 447–55.

Matzke GR . Vancomycin. In: Evans WE Schentag JJ Jusko WJ , eds. Applied Pharmacokinetics. Vancouver, WA: Applied Therapeutics, 1992: 15–1–15–31.

Farber BF Moellering RC . Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138–41.

Rice TL . Treatment of esophageal varices. Clin Pharm 1989; 8: 122–31.

Burroughs AK . Acute management of bleeding oesophageal varices. Drugs 1992; 44 (suppl 2): 14–23.

Kravetz D Bosch J Teres J Bruix J Rimola A Rodes J . Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepalology 1984; 4: 442–6.

Westaby D . The management of active variceal bleeding. Intensive Care Med 1988; 14: 100–5.

Kuret JA Murad F . Adenohypophyseal hormones and related substances. In: Gilman AG Rail TW Nies AS Taylor P , eds. Goodman and Gilman's the pharmacologic basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1334–60.

Tyden G Samnegard H Thulin L Frimar L Efendic S . Treatment of bleeding esophageal varices with somatostatin (letter). N Engl J Med 1978; 299: 1466–7.

Sonnenberg GE Keller U Perruchoud A Burckhardt D Gyr K . Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 1981; 80: 526–32.

Bosch J Kravetz D Mastai R Navasa M Silva G Chesta J Effects of somatostatin in portal hypertension. Horm Res 1988; 29: 99–102.

Bosch J Kravetz D Rodes J . Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. Gastroenterology 1981; 80: 518–25.

Jenkins SA Baxter JN Corbett W Devitt P Ware J Shields R . A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. Br Med J 1985; 290: 275–90.

Clements D Rhodes JM Elias E . Effect on oesophageal variceal pressure assessed by direct measurement. J Hepatol 1986; 2: 262–6.

Kleber G Sauerbach T Fischer G Paumgartner G . Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics. Gut 1988; 29: 153–6.

Valenzuela JE Schubert T Fogel MR Strong RM Levine J Mills PR A multi-center, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10: 958–61.

Burroughs AK McCormick PA Hughes MD Sprengers D D'Heygere F McIntyre N . Randomized, double blind, placebo-controlled trial of somatostatin for variceal bleeding. Gastroenterology 1990; 99: 1388–95.

Saari A Klvilasskso E Inberg M Paakkonen M Lahtinen J Hockerstedt K Comparison of somatostatin and vasopressin in bleeding esophageal varices. Am J Gastroenterol 1990; 7: 804–7.

Jaramillo JL de la Mata M Mino G Costan G Gomez-Camacho F . Somatostatin versus Sengstaken balloon tamponade for primary hemostasia of bleeding esophageal varices. J Hepatol 1991; 12: 100–5.

McKee R . A study of octreotide in oesophageal varices. Digestion 1990; 45 (suppl):60–5.

Swanson GM . Breast cancer in the 1990s. J Am Med Wom Assoc 1992; 47: 140–8.

Boring C Squires TS Tong T . Cancer statistics. 1992. CA Cancer J Clin 1992; 42: 19–38.

Calabresi P Chabner BA . Antineoplastic agents. In: Gilman AG Rall TW Nies AS Taylor P , eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1209–63.

Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA 1985; 254: 3461–3.

Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988; 57: 608–11.

Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987; 2: 171–5.

Kaiser-Kupfer MI Lippman ME . Tamoxifen retinopathy. Cancer Treat Rep 1978; 62: 315–20.

Kaiser-Kupfer MI Kupfer C Rodrigues MM . Tamoxifen retinopathy: A clinicopathologic report. Ophthalmology 1981; 88: 89–93.

McKeown CA Swartz M Blom J Maggiano JM . Tamoxifen retinopathy. Br J Ophthalmol 1981; 65: 177–9.

Beck M Mills PV . Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 1979; 63: 1833–4.

Vinding T Nielsen NV . Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol 1983; 61: 45–50.

Longstaff S Sigurdsson H O'Keeffe M Ogston S Preece P . A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer 1989; 25: 1805–8.

Griffiths MF . Tamoxifen retinopathy at low dosage. Am J Ophthalmol 1987; 104: 185–6.

Ashford AR Donev I Tiwari RP Garrett TJ . Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988; 61: 33–5.

Pugesgaard T Von Eyben FE . Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986; 58: 383–6.

Bentley CR Davies G Aclimandos WA . Tamoxifen retinopathy: A rare but serious complication. BMJ 1992; 304: 495–6.

Gerner EW . Ocular toxicity of tamoxifen. Ann Ophthalmol 1989; 21: 420–3.

Chang T Gonder JR Ventresca MR . Low-dose tamoxifen retinopathy. Can J Ophthalmol 1992; 27: 148–9.

Pavlidis NA Petris C Briassoulis E Klouvas G Psilas C Rempapis J Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992; 69: 2961–4.

Lullmann H Lullmann-Rauch R Wassermann O . Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlor-phentermine. CRC Crit Rev Toxicol 1975; 4: 185–218.

Oates JA Wood AJJ . Allergie rhinitis. N Engl J Med 1991; 325: 860–9.

Garrison JC . Histamine bradykinin, 5-hydroxytryptamine, and their antagonists. In: Gilman AG Rail TW Nies AS Taylor P , eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon, 1990: 575–99.

Thomas RH Browne PD Kirby JDT . The effect of ranitidine, alone and in combination with clemastine, on allergen-induced cutaneous wheal-and-flare reactions in human skin. J Allergy Clin Immunol 1985; 76: 864–9.

Lauritsen K Laursen LS Rask-Madsen J . Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (part 1). Clin Pharmacokinet 1990; 19: 11–31.

Chau NP Zech PY Pozet N Hadj-Aissa A . Ranitidine kinetics in normal subjects. Clin Pharmacol Ther 1982; 31: 770–4.

Johnson CE Weiner JS Wagner DS McLean JA . Effect of H₁-and H₂-receptor blockade on the inhibition of immediate cutaneous reactions. Clin Pharm 1984; 3: 60–4.

Smith JA Mansfield LE deShazo RD Nelson HS . An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. J Allergy Clin Immunol 1980; 65: 118–21.

Lichtenstein LM Gillespie E . Inhibition of histamine release by histamine controlled by H₂ receptor. Nature 1973; 244: 287–8.

Harvey RP Wegs J Schocket AL . A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981; 68: 262–6.

Nathan RA Segall N Schocket AL . A comparison of the actions of H₁ and H₂ antihistamines on histamine-induced bronchoconstriction and cutaneous wheal response in asthmatic patients. J Allergy Clin Immunol 1981; 67: 171–7.

Brooks CD Butler D Metzler C . Effect of H₂ blockade in the challenged allergic nose. J Allergy Clin Immunol 1982; 70: 373–6.

Reinberg A Sidi E Ghata J . Orcadian reactivity rhythms of human skin to histamine or allergen and the adrenal cycle. J Allergy 1965; 36: 273–83.